Exchange: NASDAQ·Updated 07:13 PM EDT

About SNGX

About

Soligenix, Inc.. The Group's principal activity is to research and develop biodefense vaccines and oral therapeutic products intended for areas of unmet medical need. The Group operates through two segments: The BioDefense segment develops vaccines to combat the threat posed by two potent biological toxins, ricin toxin and botulinum toxin. The vaccines in BioDefense segment are considered bioterrorism threats by the US Department of Homeland Security, National Institute of Allergic and Infectious Diseases, Department of Defense and Centers for Disease Control and Prevention. The BioTherapeutics segment is in the process of developing oral therapeutic products to treat unmet medical needs. OrBec has been evaluated in a randomized, multi-center, double-blinded, placebo-controlled pivotal Phase 3 clinical trial for the treatment of GI GVHD, a serious and life-threatening gastrointestinal inflammation associated with allogeneic bone marrow or stem cell transplant therapy.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
14

Frequently Asked Questions

What is Market Cap of Soligenix Inc?
What is the 52-week high for Soligenix Inc?
What is the 52-week low for Soligenix Inc?
What is Soligenix Inc stock price today?
What was Soligenix Inc stock price yesterday?
What is the PE ratio of Soligenix Inc?
What is the Price-to-Book ratio of Soligenix Inc?
What is the 50-day moving average of Soligenix Inc?
How many employees does Soligenix Inc have?

Advertisement|Remove ads.